K. Amundson

Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies.

R. Simon, W. Levin, A. Erbersdobler, 2011, Cancer research.

Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector

Harry E. Gruber, Joan M. Robbins, J. Hlavaty, 2011, Neuro-oncology.

Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3

P. O'Connor, M. McTigue, S. Yamazaki, 2008, Clinical Cancer Research.

Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression.

D. Lohse, K. Hiraoka, N. Kasahara, 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

Dual functional monoclonal antibody PF-04605412 targets integrin alpha5beta1 and elicits potent antibody-dependent cellular cytotoxicity.

S. Bender, Lianglin Zhang, S. Bergqvist, 2010, Cancer research.

Intratumoral conversion of flucytosine to 5-fluorouracil using a novel MLV-based replication-competent retroviral vector carrying the cytosine deaminase gene (Toca 511) in an immune-competent model of glioblastoma.

W. Günzburg, H. Gruber, J. Robbins, 2010 .

Erratum: Design and selection of toca 511 for clinical use: Modified retroviral replicating vector with improved stability and gene expression (Molecular Therapy (2012) 20 (1689-1698) DOI:10.1038/mt.2012.83)

D. Lohse, K. Hiraoka, N. Kasahara, 2013 .

CD388: A universally protective Drug-Fc Conjugate that targets influenza virus neuraminidase

J. Levin, Alain Noncovich, K. Amundson, 2024, bioRxiv.